Tryptamine Therapeutics (ASX:TYP) | Webinar with Jason Carroll | 28/08/24

Watch our webinar with Tryptamine Therapeutics, featuring CEO Jason Carroll.
The webinar commences with a presentation by Jason, followed by a live Q&A with the audience.
Tryptamine Therapeutics Limited (ASX: TYP) is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.
//
The information provided in our webinars are for general advice purposes only and should not be construed as a recommendation or endorsement of any financial product or security.
Sharewise is a stock trading platform seamlessly integrated with expert advice. We will be launching later this year. Keep an eye out for updates.
Website: www.sharewise.com.au
Facebook: / sharewiseau
LinkedIn: / sharewiseau
Instagram: / sharewise
TikTok: / sharewiseau